Behavioral and Pharmacological Reconsolidation Interference in Misophonia
NCT05928689 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 141
Last updated 2024-10-16
Summary
One of the core processes presumably underlying misophonia - a condition characterized by decreased tolerance for specific sounds - is associative learning. Using behavioral, computational, and neural analyses of emotional learning and memory processes to understand the unknown behavioral and neural mechanisms underlying misophonia's associative learning and memory, the study team will evaluate whether interference with the reconsolidation of a reactivated misophonia memory with propranolol can alleviate aversive reaction to misophonia-related cues.
Conditions
- Misophonia
Interventions
- DRUG
-
Propranolol Hydrochloride tablet
Single dose of 40 mg propranolol tablet
- BEHAVIORAL
-
Reminder
Reactivation of misophonia trigger memory
- BEHAVIORAL
-
Counterconditioning
Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.
- DRUG
-
Matching placebo tablet
Sponsors & Collaborators
-
Icahn School of Medicine at Mount Sinai
lead OTHER
Principal Investigators
-
Daniela Schiller, PhD · Icahn School of Medicine at Mount Sinai
-
James Murrough, MD, PhD · Icahn School of Medicine at Mount Sinai
-
Laili Soleimani, MD, Msc · Icahn School of Medicine at Mount Sinai
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-02
- Primary Completion
- 2024-09-30
- Completion
- 2024-09-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance
NCT01243060 ·Status: COMPLETED ·Phase: NA
-
Behavioral and Pharmacological Treatment for Insomnia
NCT00042146 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients
NCT01951053 ·Status: COMPLETED ·Phase: PHASE1
-
Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T
NCT01747590 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Solriamfetol and CBT-I in Patients With Insomnia Disorder
NCT05838430 ·Status: COMPLETED ·Phase: PHASE4
-
Cognitive-Behavioural and Hypnotic Treatment of Chronic Primary Insomnia Among the Elderly
NCT00295386 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Determine Whether Ramelteon Helps People With REM Sleep Behavior Disorder
NCT01401413 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia
NCT06062953 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag
NCT00097474 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Chronic Hypnotic Use
NCT01006525 ·Status: COMPLETED
-
Insomnia Behavioral Intervention Study
NCT05301543 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs
NCT00683436 ·Status: TERMINATED ·Phase: PHASE2
-
Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.
NCT00414102 ·Status: COMPLETED ·Phase: PHASE4
-
Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
NCT00177216 ·Status: COMPLETED ·Phase: PHASE4
-
Magnetoencephalographic (MEG) Localization of Ramelteon's Effects on Brain Function and Cortical Arousal in Insomnia
NCT00688025 ·Status: COMPLETED
-
An Observation Study on Neuropsychology and Serum Melatonin Level in Patients With Medication Overuse Headache
NCT03655184 ·Status: UNKNOWN
-
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
NCT00745030 ·Status: TERMINATED ·Phase: NA
-
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
NCT03353922 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability
NCT00368056 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug
NCT04299490 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Tolerability of Tasipimidine in Sleepless Patients
NCT06956495 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study
NCT02836743 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
NCT00878553 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)
NCT00798395 ·Status: COMPLETED ·Phase: PHASE1
-
Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)
NCT00296790 ·Status: COMPLETED ·Phase: PHASE4